Most Clicked StoriesMore >


New white paper outlines how FDA can increase prescription drug competition to reduce costs

PCMA SmartBrief | Nov 17, 2014

A new white paper authored by Alex Brill, CEO of Matrix Global Advisors, presents options policymakers can consider for lowering drug costs. The FDA should approve competing brands and generic drugs faster and should issue final guidance for developing biosimilar drugs, the PCMA paper says. Politico (11/17)


Speeding up the approval process for generic drugs can lower prices

PCMA SmartBrief | Nov 19, 2014

AARP report shows brand-name drug prices soaring

PCMA SmartBrief | Nov 20, 2014

Congressional Research Service: Medicaid rebates may add to high drug prices

PCMA SmartBrief | Nov 19, 2014

Refill reminders boost adherence in study participants

PCMA SmartBrief | Nov 18, 2014

Biologic drug market competition is hampered by FDA

PCMA SmartBrief | Nov 20, 2014

PCMA: Seniors will pay more under independent drugstores' plan

PCMA SmartBrief | Nov 21, 2014

U.S. diabetes care costs soar, study finds

PCMA SmartBrief | Nov 21, 2014

Critics question Tufts report on cost of drug development

PCMA SmartBrief | Nov 19, 2014

Read the white paper from PCMA

PCMA SmartBrief | Nov 17, 2014


Find PCMA SmartBrief Issues by Date:





Sign up for PCMA SmartBrief



Designed specifically for PBM industry professionals, PCMA SmartBrief is a FREE, daily e-mail newsletter. It provides the the most relevant and actionable PBM industry news in a quick, easy to read format. Learn more